Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed
French Pharma Reports €1.33Bn Q1 Consumer Health Sales Helped By Price Increases
After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.
You may also be interested in...
UK Cialis Rx-To-OTC Switch World-First For Sanofi, H2 2023 Launch Planned
The UK is the first country to allow OTC access to Sanofi's tadalafil-based erectile dysfunction drug Cialis following a successful switch. Approved as a pharmacy medicine, Sanofi will launch Cialis Together in the second half of the year. Cialis will compete against Viatris' sildenafil-based Viagra Connect in the men's sexual health and wellness category, which has seen a proliferation of products in recent months.
German Government Wants Sildenafil, Tadalafil OTC
Germany's Ministry of Health surprised all those present at a recent BAH meeting by announcing it would like to see erectile dysfunction drugs like sildenafil and tadalafil available OTC. Such a move, however, would put the government at odds with drug regulator BfArM's Expert Committee for Prescription, which recently rejected an application for the Rx-to-OTC switch of sildenafil.
US OTC Switch For Cialis At Top Of To-Do List For Sanofi’s North American Consumer Health Chief
Andrew Loucks moves to Sanofi from helm of consumer health and technology firm Sensory Cloud as business navigates gaining US OTC heartburn market share for Zantac brand, which it relaunched with famotidine replacing ranitidine as the active ingredient.